ABSTRACT -Warfarin is commonly used worldwide as a rodenticide. It inhibits coagulation of blood by inhibiting vitamin K 2,3-epoxide reductase (VKOR) activity. An inadequate supply of vitamin K blocks the production of prothrombin and causes hemorrhage. It has been reported that repeated or long-term treatments with this drug cause resistance in wild rodents. However, the mechanism of warfarin resistance vitamin K epoxide reductase complex subunit 1 (VKORC1), which is the main unit of VKOR. An amino acid substitution in VKORC1 is one of the supposed mechanisms of warfarin resistance. An acceler--farin metabolism in warfarin-resistant rats. Meanwhile, the appearance of warfarin-resistant rodents has led to the development of the more effective and toxic rodenticide superwarfarin, which is widely used in Europe and the USA. However, animals resistant to this second-generation rodenticide have already been reported in Europe. In this review, we focus on the mechanism and the pleiotropic effects of pesticide resistance in wild rodents.
INTRODUCTION
Brown rats (Rattus norvegicus), roof rats (R. rattus), and house mice (Mus musculus domesticus) live in close proximity to humans. They may carry pathogens of infectious diseases, such as plague, hemorrhagic fever with renal syndrome (HFRS), Weil's disease, hepatitis E, and others. For pest control, rodenticides are the most effective tool, and several types have been developed, e.g., -oacetamide (1081), and hypercalcemics. Above all, coumarin-derived anticoagulants such as warfarin are commonly used to control rat populations worldwide due to their convenience, safety, and minimal impact on the environment.
Warfarin has been widely and continuously used since the 1950s for pest control. It is well known that frequent insecticide treatments cause resistance in the target insect species. Like insecticides, the repeated use of warfarin has caused drug resistance in wild rodent species. Table 1 shows the appearance locations of warfarin-resistant rodents in the world. Resistance to warfarin was first observed in Scotland in 1958 (Boyle, 1960) , and warfarin resistance in the house mouse (M. musculus domesticus) was evident shortly thereafter (Dodsworth, 1961) . Since then, resistant rats have been reported all over the world, in Great Britain (Boyle, 1960) , Denmark (Lund, 1967) , Germany (Telle, 1971) , and Belgium (Lund, 1984) . Myllymäki (1995) reported resistant rodents in Finland and France. The majority of reports came from Europe, but resistance in commensal rodents was also documented in the USA (Jackson and Kaukeinen, 1972) , Canada (Siddiqi and Blaine, 1982) , and Australia (Saunders, 1978) . These "super rats" are also found around Tokyo, Japan (Naganuma et al., 1981) , and warfarin-resistance has led to failure of their control using warfarin as a rodenticide.
However, the precise mechanism of warfarin resistance
Pesticide resistance in wild mammals -Mechanisms of anticoagulant resistance in wild rodents -in rodents is still not known. In this review, we focus on the mechanisms of pesticide resistance in rodents.
MUTATION IN TARGET MOLECULE OF WARFARIN

Vitamin K cycle and target molecule of warfarin
The production and activation of coagulation factors VII, IX, X and prothrombin are dependent on the vitato gamma carboxyl glutamate is required for the activity of vitamin K-dependent proteins ( Fig. 1) (Stafford, 2005) . The carboxylated Glu residue is converted to a Gla amino acid and a reduced vitamin K molecule is converted to vitamin K epoxide. Before vitamin K can be reused in the vitamin K cycle, vitamin K epoxide must be converted back to reduced vitamin K by vitamin K 2,3-epoxide reductase (VKOR). Recently, Wajih et al novel endogenous molecules that transfer the electron to VKOR and regenerate the vitamin K cycle (Wajih et al., 2005 (Wajih et al., , 2007 .
The pharmacological target of warfarin is VKOR. Through inhibition of VKOR, warfarin blocks the vita--min K-dependent blood-clotting factors. An inadequate supply of vitamin K blocks the production of prothrombin and leads to hemorrhaging (Furie and Furie, 1988; Suttie, 1985; Helgeland, 1977; Thijssen et al., 2004; Cain et al., 1998) .
Mutation at position of 139 in vitamin K epoxide reductase Thijssen et al. (1989) reported that VKOR activity in liver microsomes of resistant rats was not inhibited by warfarin. They also reported that the basal VKOR activity in warfarin-resistant rats was remarkably lower than that of warfarin-sensitive animals. Thus, a mutation of the VKOR gene and conformation of the protein structure is a possible mechanism of warfarin resistance.
In 2004, two research groups identified and reported a novel molecule that contributes to VKOR activity in the rat and named it vitamin K epoxide reductase complex subunit 1 (VKORC1) (Rost et al., 2004; Li et al., 2004) . VKORC1 is an 18 kDa hydrophobic protein resident in the endoplasmic reticulum membrane. Hydrophobicity plots and secondary structure predictions suggest a - et al. (2004) suggested that warfarin resistance in rats was attributable it was shown that the C132-X-X-C135 motif in VKO-RC1 comprises part of the site of redox activity that catalyzes the vitamin K epoxide reduction (Rost et al. 2005 ; et al. (2005) showed the current status of anticoagulant resistance in commensal rats and house mice -ed to be responsible for warfarin resistance (Table 1) . In European rats, and especially, the substitution at the 139 codon position is the most common and potent candidate for resistance to warfarin. They also reported that the Thr--ance of VKOR activity toward warfarin when this mutatet al., 2005) .
Compensatory molecule for loss of VKOR in warfarin-resistant rats
The VKORC1 139 mutation in warfarin-resistant rats causes a structural conformation of the VKORC1 protein, and this conformation prevents warfarin blocking (Rost et al., 2005) . In addition to resistance to warfarin, this mutation may cause a dysfunction or drastic suppression of vitamin K epoxide reduction and induce compensatory mechanisms to maintain blood clotting. The VKOR activity of warfarin-resistant animals is drastically lower than that of normal animals, and how warfarin-resistant rats survive with markedly low or almost non-existent VKOR activity has been an unanswered question. Although the system that supports the loss of VKOR activity via the VKORC1 molecule is still unclear, one possible mechanism to explain the survival of warfarin-resistant rats under the condition of defective VKOR activity is resupply of exogenous vitamin K in resistant rodents (Markussen et al., 2003) .
Warfarin resistance has been often shown to be associated with unexpected effects, particularly with an increased dietary requirement for vitamin K. Markussen et al. (2003) reported a moderately increased requirement for vitamin K in Danish homozygous rats resistant to warfarin compared to heterozygous resistant rats. Heiberg et al. (2006) showed that moderately warfarin-resistant females were better breeders than highly resistant females in the environmental condition without anticoagulant selection. They suggested that in males highly tolerant to rodenticides, the selection presumably takes place at the immature stage, whereas in females the vitamin K requirement becomes crucial at the reproductive stage because vitamin K is not only essential for the blood clotting process but also for bone formation. The drastically suppressed vitamin K production in highly tolerant females might not be able to support the reproductive function. Thus, heterozygous resistant females, which have a much lower vitamin K requirement, will dominate Inhibition of VKOR produces abnormal coagulation factor and causes fatal hemorrhage. VitK: vitamin K.
the reproduction in resistant rats (Heiberg et al., 2006) . -ciency in anticoagulant-resistant rats during reproduction may be useful information for pest control.
Kinetics analyses of VKOR in warfarin-resistant and -sensitive brown rats
Although further study is needed to clarify how anticoagulant-tolerant rats survive with markedly reduced VKOR activity and acquire warfarin resistance at the same time, Lasseur et al. showed one reasonable hypothesis for this problem. Lasseur et al. (2006) reported that warfarin resistance in brown rats in France was attributable to a mutation which is supposed to be one of the warfarin-binding sites, caused low VKOR activity (low V max ) in warfarin-resistant brown rats. However, a very low K m of VKOR activity in the French warfarin-resistant rats led to equal or V max /K m ) than in warfarin-sensitive rats. Thus, Lasseur et al. showed that at physiologically low concentrations of the substrate (vitamin K epoxide), the substituted VKORC1 molecule can supply high enough levels of reduced vitamin K to allow the vitamin K cycle to function.
Kinetics analyses of VKOR in warfarin-resistant and -sensitive mice
In addition to the rat VKOR, Lasseur et al. also determined the kinetic parameters of warfarin-resistant mice (M. musculus domesticus) (Lasseur et al., 2006) . They suggested that warfarin resistance in mice was relat-VKORC1 gene as in the warfarin-resistant rat. In their report, they suggested that the enzymatic model was com---capacity. They estimated that component A is very sensitive to warfarin and that B appears to be more resistant, requiring 20-30 fold higher Ki values. However, the reason why the mice acquired resistance to warfarin was unanswered in their report, because there was no clear difference between the kinetic parameters of components A and B of susceptible and resistant mice.
V max /K m was lower in warfarin-resistant than that in -susceptible mice, unlike the previous report on rats (Lasseur et al., 2006) . The Ki values were similar in warfarin-resistant and -sensitive animals. Thus, mutations in VKORC1 alone cannot explain all aspects of resistance in this rodent. located in the endoplasmic reticulum. The system modiadding an extra carboxyl group onto the carbon of speGla residues, which bind calcium (Suttie, 1985) .
Wallin et al in VKORC1 in warfarin-resistant rodents (Wallin and Hutson, 2004) . Wallin showed that the calumenin expression level was higher in resistant rats than in sensitive rats. They also demonstrated that overexpression of calumenin inhibits the warfarin inhibition of VKOR-dependent activity (Wallin et al., 2001) .
WARFARIN METABOLISM IN RESISTANT RODENTS Cytochrome P450
to metabolize warfarin (Daly et al comprise a superfamily of monooxygenases and are -ygenase system plays a central role in oxidative metabolism or biotransformation of a wide range of comcan metabolize numerous endogenous compounds such as steroids, bile acids, fatty acids, and prostaglandins. In most important enzymes to eliminate foreign chemicals, e.g., drugs, chemical carcinogens, and environmental polfor the catalytic cycle. Metabolically transformed foreign compounds are conjugated with larger endogenous molecules with the aid of different families of transferase enzymes (e.g., glutathione S -curonosyltransferase) (Hayes et al., 2005; Guillemette, 2003) . 
Warfarin metabolism
In humans, anticoagulation therapy with warfarin has traditionally posed a challenge to clinicians. Warfarin is a racemic mixture of two enantiomers, the (R) and (S) forms, and the warfarin (S)-enantiomer is 3-5 times more potent than the (R)-enantiomer (Kaminsky and to about 80% of the metabolism of the (S)-enantiomer of warfarin to 7-hydroxywarfarin. Several studies also sugincreased risk of adverse reactions to warfarin in humans (Kirchheiner and Brockmöller, 2005) . The (R)-enantiomer is metabolized to 6-, 7-, 8-, and 10-hydroxywarfarin by -macokinetics of (R)-warfarin (Uno et al., 2008) .
In rats, warfarin hydroxylations are mainly catalyzed 8-or 10-OH warfarin in rats (Guengerich et al., 1982) , and these primary metabolites are made more water-solin urine, as in the metabolic pathway in humans.
rats Sugano et al. (2001) newly reported the potent resistance of wild roof rats in the Tokyo area of Japan to warfarin. They focused on the low level of mRNA exprescatalyzes warfarin 10-hydroxylation in resistant rats, and concluded that reduced metabolic activation of warfarin might cause the resistance. However, it has been reportanticoagulant effect and increases the tolerance for higher doses of warfarin in humans (Izzo, 2005) . In addition, higher in liver microsomes from warfarin-resistant roof rats than those from -sensitive animals (Ishizuka et al., 2007) .
In insects, elevation of the ability to detoxify foreign chemicals by the induction of enzyme expression or genetic-polymorphism allows them to adapt to an insecticide-contaminated environment (Scott, 1999) . In mammals, exposure to environmental pollutants such as pesticides might be the fatal stress for a small species. Thus, to adapt to the polluted environment, it is possible that 3A2 contribute to warfarin metabolism. Vol. 33 No. 3 pesticides. In a previous study, warfarin levels in plasma were lower in warfarin-resistant than in -sensitive animals after warfarin administration (Ishizuka et al., 2007) . Warfarin metabolic activities in resistant rats were higher than those in sensitive rats. This may be the reason for high activities in every pathway of warfarin metabolism in resistresistance, resistant roof rats were treated with feed con- (Ishizuka et al., 2007) . The increased rate of mortality in rats co-treated with warfarin and SKF-525A indicated might contribute to warfarin resistance in wild rodents. It -farin metabolism also gave rise to warfarin resistance in wild rats.
SUPERWARFARIN AGAINST RESISTANT RODENTS
New generation of anticoagulants
More than 60 years ago, the discovery that dicoumarol was the causative agent of haemorrhagic disease in cattle fed spoiled sweet clover hay spurred the development of the 4-hydroxycoumarins. This led to the discovery of warfarin as a rodenticide. Now, due to the resistance to warfarin in wild rodents, a new generation of anticoagulants has been developed -ic warfarins are called superwarfarins, and are categorized in two groups: 4-hydroxycoumarins (e.g., brodifacoum, bromodialone, and difenacoum) and the inadione derivatives (e.g., diphacinone and chlorphacinone) (World Health Organization, 1995) . Like warfarin, the target molecule of these superwarfarins is vitamin K epoxide reductase. Superwarfarins are toxins characterized by an extremely long half-life and a potent fatal activity comparable to warfarin. Superwarfarin has already been marketed in over-the-counter rodenticides.
This potent toxic superwarfarin has been used worldwide to effectively control rats. However, there are two problems to note in the continuous use of superwarfarin for pest control, as follows.
Poisoning of non-target species
The first point is the recent increase in superwarfarin poisoning in non-target animals, including humans (Ayala et al., 2007; Spahr et al., 2007; Stone et al., 1999; Kotsaftis et al., 2007) . Especially, superwarfarin has caused primary and secondary poisonings of wild birds.
Rodenticides were used to eradicate invasive rodents on islands in New Zealand. However, the use of superwarfarin for the eradiation of invasive rodent populations on islands caused a drastic reduction in the number of wild birds (Johnston et al., 2005; Eason et al., 2001) . As shown in Table 2 , superwarfarin possessed potent toxicity not only in rodents but also non-target species
Resistance against second-generation rodenticide
The second point of concern is the possibility of the appearance and distribution of resistance against superwarfarin in the rats surviving frequent superwarfarin exposures. Already, many single nucleotide polyaround Europe, which are suggested to cause resistance et al., 2005) . In addition, elevation of the ability to detoxify foreign chemicals due to the induction of enzyme expression or genetic-polymorphism in wild rodents may allow them to adapt to a rodenticidecontaminated environment. Exposures to environmental pollutants such as pesticides might induce the expression -cation, as shown in the report on the Tokyo resistant rat (Ishizuka et al., 2007) . Fujita et al. (2001) also report- In the future, it is possible that the continuous and potent fatal stress by abuse of superwarfarin willause the selection of adaptive gene(s) and lead to distribution of the second "super rat". Already rats resistant to the toxicity of the second-generation rodenticide have been found in areas of Europe (Kohn et al., 2000 (Kohn et al., , 2003 .
PERSPECTIVES ON THE FUTURE
The evolutional adaptation of mammals to a polluted environment is very interesting because these phenomena are usually observed in short-lived invertebrate species such as insects. Recently, we found novel warfarinresistant brown rats in several areas of Japan in addition to the roof rats in the Tokyo area (data not shown). There were individual differences in the resistance potency to warfarin. We have analyzed the VKORC1 gene seqnenc--farin-resistant Tokyo roof rats and novel resistant brown -stitutions at codon 139 in the Japanese warfarin-resistant rats. Thus, we now suggest that the mechanism of warfarin resistance may not arise simply from the VKORC1 139 mutation alone, but may vary according to the area of habitation (or environment). We also suggest the possibility of mixed mechanisms of warfarin resistance, e.g., (Fig. 3) . In addition, several types of rodents tolerant to anticoagulant rodenticides might acquire the ability to resupply vitamin K outside the VKOR-dependent cycle. We expect that studies of the novel resistant rodent will clarify these points in the future.
The next step in pest control has usually been to switch to a more powerful and effective substance when resist-- Fig. 3 . Mechanisms for resistance against anticoagulant rodenticides. It is possible that several mechanisms contribute to warfarin tion of the detailed mechanisms of rodenticide tolerance may establish a new approach to using rodenticides for pest control.
